Method for treating acute myeloid leukemia
The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC105P.
1. A method for treating acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient an effective amount of a compound of formula (I) or a salt, solvate or prodrug thereof
wherein the effective amount administered to the patient is from about 0.05 to 18 mg/kg body weight per day.
2. The method of claim 1 wherein the patient is a human subject.
3. The method of claim 1 wherein the effective amount administered is from about 0.4 mg to 16 mg/kg body weight per day.
4. The method of claim 1 wherein the compound is administered by parenteral administration.
5. The method of claim 1 wherein the compound is co-administered simultaneously or sequentially with another anti-cancer agent.
6. The method of claim 1 wherein the patient is selected for treatment based on clinical parameters including age, level of progression of the disease, and/or other complicating ailments.
7. A pharmaceutical kit for treating AML in a patient in need thereof comprising the compound of formula (I):
together with instructions for administering the compound to the patient.
8. The method according to claim 1 wherein the compound of formula (I) is: